Myeloproliferative Neoplasm Research Consortium
Official title: Myeloproliferative Neoplasms-Research Consortium
Funded at Icahn School of Medicine at Mount Sinai · NIH-11399011 · Data updated 2026-11-12
A large research collaboration across multiple centers aims to improve survival for patients with myelofibrosis and related myeloproliferative neoplasms through coordinated laboratory, translational, and clinical work.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 1, 2006 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $4,093,102 |
| NIH project number | 5P01CA108671-18 |
| Project ID | NIH-11399011 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with myelofibrosis or related myeloproliferative neoplasms who are not candidates for stem cell transplantation and who seek longer survival and better symptom control.
✕Less likely to help
Patients with conditions outside the scope of MF/MPN or those who are not eligible for trial-related efforts may not benefit.
What this research studies
This NIH-funded program brings together scientists from 13 institutions to develop and test new treatment approaches for myelofibrosis and other MPNs. It builds on 14 years of collaboration to identify therapeutic strategies that go beyond first-generation JAK2 inhibitors. The consortium focuses on translating lab discoveries into clinical options for patients who are not candidates for stem cell transplantation. The project coordinates research across basic biology, translational studies, and patient care to extend survival and quality of life for people with MF and related conditions.
Why it matters
Potential benefit: If successful, patients with myelofibrosis and related MPNs could gain more effective, disease-modifying therapies and improved survival.
How similar studies have gone: A long-running collaboration has previously contributed to understanding MF and expanding therapeutic options, though disease-modifying advances remain ongoing.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Hoffman, Ronald — Icahn School of Medicine at Mount Sinai
- Study coordinator: Hoffman, Ronald
Related research
Other NIH-funded projects on the same topics.
-
Biomarker clues to catch pancreatic cancer early in cysts
A study from UC San Diego is testing blood and cyst-fluid markers to help tell high-risk pancreatic cysts from low-risk ones so that people with pancreatic cysts can get the right care sooner.
-
Understanding how different CALR mutations drive certain blood cancers
This grant explores how two CALR mutation types cause myeloproliferative neoplasms and could lead to better treatments for people with these blood cancers.
-
Cell Competition in Myeloproliferative Neoplasms
This NIH grant explores how healthy and mutant blood stem cells interact in certain blood cancers to understand why some patients progress and how future therapies might help.
-
Targeting ERK’s brake pedals to slow cancer progression
Aims to block the parts of ERK signaling that speed up cancer progression, by guiding drugs to the substrate-binding domains that act like accelerator pedals in myeloproliferative neoplasms and related cancers.
-
Biomarker work to predict pancreatic IPMN cancer risk
A Duke University researcher is testing biomarkers to tell which pancreatic IPMN cysts are likely to become invasive cancer.
-
Understanding how inflammation and biology drive blood cancer evolution
A large, multi-project program at Washington University is exploring how inflammatory signals and cell-intrinsic factors work together to drive progression of myeloproliferative neoplasms in people.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.